Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS by Cao, Shengbo et al.
RESEARCH Open Access
Lentiviral vector-mediated stable expression of
sTNFR-Fc in human macrophage and neuronal
cells as a potential therapy for neuroAIDS
Shengbo Cao
1,3†, Chengxiang Wu
1†, Yongbo Yang
1, Lynn F Sniderhan
2, Sanjay B Maggirwar
2, Stephen Dewhurst
2
and Yuanan Lu
1*
Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) infection frequently causes neurologic disease, which
is the result of viral replication and activation of macrophages and microglia in the CNS, and subsequent secretion
of high levels of neurotoxic products, including tumor necrosis factor-a (TNF-a). We therefore hypothesized that a
soluble TNF-a antagonist might have potential utility as a neuroprotective effecter molecule, and conducted proof-
of-concept studies to test this hypothesis.
Methods: To develop novel therapeutics for the treatment of neuroAIDS, we constructed and characterized a
soluble TNF receptor (sTNFR)-Fc fusion protein with the goal of neutralizing TNF-a, and tested the stability of
expression of this gene following delivery by a lentiviral vector.
Results: High-titer lentiviral vectors were prepared, allowing efficient transduction of macrophage/glial and
neuronal cell lines, as well as primary rat cerebellar neurons. Efficient, stable secretion of sTNFR-Fc was
demonstrated in supernatants from transduced cell lines over 20 passages, using both western blot and ELISA.
Biological activity of the secreted sTNFR-Fc was confirmed by TNF-specific in vitro protein binding and functional
blocking assays. Finally, the secreted protein was shown to protect neuronal cells from TNF-a, HIV-1 Tat-, and
gp120-mediated neurotoxicity.
Conclusions: These results demonstrate that lentiviral vector mediated expression of sTNFR-Fc may have potential
as a novel therapy for neuroAIDS.
Background
HIV-1 associated neurocognitive disorders (HAND),
which include asymptomatic neurocognitive impairment
(ANI), minor neurocognitive impairment (MND), and
HIV-associated dementia (HAD), remain among the
most common disorders in people infected with HIV,
even in an era when potent antiviral therapy is widely
deployed [1]. Indeed, a 2010 study published by the
CHARTER Group showed that 52% of HIV-infected
adults in a large multisite cohort of more than 1,500
subjects exhibited signs of neuropsychological (NP)
impairment, despite the fact some 71% of the persons
enrolled in the cohort were receiving combination anti-
retroviral therapy (cART) at the time of the study [2].
A N Iw a st h em o s tc o m m o ns u b d i a g n o s i si np e r s o n s
with HAND, suggesting that cART may alter the pre-
sentation/severity of HAND - even if it has not dramati-
cally changed the overall rate of this disease. This is
consistent with reports of more pronounced impairment
of executive function and memory/learning in the cART
era, compared to the pre-CART period [3]. The inability
of cART to prevent HAND, and the failure of many
anti-HIV-1 drugs to adequately penetrate the blood-
brain barrier (BBB) [4,5], therefore suggest a need for
new treatments for this disease.
I nt h eb r a i n ,o n l ym a c r o p h a g e sa n dm i c r o g l i aa r ep r o -
ductively infected by HIV-1 and able to serve as a reservoir
for production of progeny virus [6,7]. HIV-1 replication
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brain macrophages and microglia, leading to the secretion
of proinflammatory cytokines, particularly TNF-a. TNF-a
interacts with two distinct types of cell surface receptors,
designated TNF receptor types 1 and 2 (TNFR1, p55 and
TNFR2, p75) [8]. TNF-a increases the permeability of the
blood-brain barrier, allowing HIV-1-infected monocytes to
enter the brain [9]; it also mediates direct neurotoxic
effects [10-15].
Present evidence has shown that antagonism of TNF-
a by expression of sTNFR can ameliorate inflammatory
diseases such as rheumatoid arthritis or reduce TNF-a
mediated cytopathicity [16-22]. To explore the efficacy
of using genetically modified monocyte/macrophage to
deliver sTNFR into the central nervous system (CNS)
as a novel treatment for neuroAIDS, we constructed
and analyzed an HIV-1-based vector that expresses
sTNFR-Fc under the transcriptional control of the
human cytomegalovirus (CMV) promoter. This vector
was shown to transduce human macrophage and neu-
ronal cell lines stably with high efficiency in vitro,
resulting in the secretion of high levels of the sTNFR-
Fc product. Protein production from the vector-trans-
duced cells remained stable for 20 in vitro passages,
and the transgene product was shown to be biologically
effective as expected (i.e., to functionally block TNF-a
activity). Finally, the secreted TNFR-Fc protein was
shown to be protective to primary neurons that were
exposed to the candidate HIV-1 neurotoxins, Tat and
gp120. These studies lay the groundwork for future
studies of using sTNFR as a novel therapeutic approach
for neuroAIDS.
Methods
Cell lines and culture
Human embryonic kidney (HEK) 293T cells were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Sigma-Aldrich, St. Louis, MO) containing 1.0 g/L glu-
cose, 2 mM L-glutamine, 100 IU/mL penicillin (Sigma-
Aldrich), 0.1 mg/mL streptomycin (Sigma-Aldrich) and
10% fetal bovine serum (FBS) (HyClone, Logan, UT). A
human neuroblastoma cell line (HTB-11; aka SK-N-SH)
and a mouse fibroblast cell line (L929) were cultured in
Minimum Essential Medium (Eagle) (MEM) (Sigma-
Aldrich) supplemented with 2 mM L-glutamine, 1.0
mM sodium pyruvate, 100 IU/mL penicillin (sigma), 0.1
mg/mL streptomycin (Sigma-Aldrich) and 10% FBS. The
human embryonic microglial cell line (CHME-5) was
cultured in Dulbecco’s Modified Eagle’sM e d i u m
(DMEM) (Mediatech, Inc., Herndon, VA) containing 4.5
g/L glucose, 2 mM L-glutamine, 100 IU/mL penicillin
(Sigma-Aldrich), 0.1 mg/mL streptomycin (Sigma-
Aldrich) and 10% FBS.
Primary Neuronal Cultures
Seven-day-old Sprague-Dawley rats were sacrificed fol-
lowing carbon dioxide inhalation (anesthesia to minimize
pain and discomfort) and cerebellar brain tissue was har-
vested in accordance with Animal Welfare Act and NIH
guidelines. The methods used have been described pre-
viously [20-22]. In brief, cerebellum was collected,
washed, and separated into a single-cell suspension using
gentle trypsinization, trituration with a polished glass pip-
ette, and filtration through nylon mesh. Following Percoll
density gradient centrifugation to remove glia, the neu-
rons were collected and washed twice in sterile medium
without serum, then resuspended in DMEM/F12 Medium
with 10% horse serum. Cells were then plated on poly-L-
lysine (70K-150K MW; Sigma)-coated 100 mm culture
dishes at a density of 3 × 10
6 cells per dish. One day
later, 5-fluorodeoxyuridine (20 mg/ml) and uridine (50
mg/ml) were added to eliminate proliferative cells (astro-
cytes); the purity of the neuronal population was verified
by immunocytochemical staining for microtubule-asso-
ciated protein-2. Under these conditions, the cultures
were >95% homogeneous for neurons. Neurons were cul-
tured for ≤ 7 days at 37°C in a humidified atmosphere
containing 5% CO2; and suspended in serum-free
DMEM/F12, for 24h prior to the treatments.
Generation of a HIV-1-based lentiviral vector containing
an expression cassette for a human soluble TNF-a
receptor (sTNFR)-Fc fusion protein
A transfer plasmid containing an expression cassette for
sTNFR-Fc fusion protein (Figure 1) was constructed.
Figure 1 Lentiviral vector mediated delivery and expression of
sTNFR-Fc. (A) Schematic maps of the lentiviral transfer plasmids,
pHR-hTNFR-Fc-eGFP and pHR-Fc-eGFP. LTR: long terminal repeat; ψ:
packaging signal; SA, SD: splice donor, splice acceptor; CMV:
cytomegalovirus promoter; hTNFR-Fc: codon-optimized gene
encoding the extracellular domain of the human TNF receptor type
2, fused to the hinge domain from IgG1 and the Fc domain from
human IgG3; Fc: hinge domain from IgG1 and the Fc domain from
human IgG3; IRES: internal ribosome entry site; GFP: green
fluorescent protein.
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sTNFR-Fc fusion protein was commercially synthesized
(GeneArt). This gene contained the extracellular domain
of the human TNF receptor type-2 fused through its
carboxyl-terminal to the hinge domain from the human
IgG1 gene and the Fc domain from the human IgG3
gene. The synthetic gene was then amplified by PCR,
using primers containing Xho Ia n dSac II restriction
sites within the 5’ and 3’ termini, respectively, and
inserted into the pHR-HB7-IRES-GFP plasmid (gener-
ously provided by Dr. V. Planelles, University of Utah)
that was digested with the same enzymes. The final
bicistronic plasmid construct, pHR-hTNFR-Fc-eGFP,
expressed the sTNFR-Fc fusion protein and the green
fluorescent protein (GFP). A DNA fragment encoding the
hinge domain from human IgG1 and the Fc domain
from human IgG3 was also amplified similarly through
PCR and cloned into the same lentiviral vector plasmid
through Xho Ia n dSac II digestion and ligation, and used
as a control without the TNF-a receptor. Lentiviral vec-
tors encoding the sTNFR-Fc fusion protein, or the Fc
fragment alone, were then produced by transient trans-
fection of 293T cells. Vector production, concentration,
and titration were performed as described [23-25], except
that 293T cells were used for vector titration and initial
detection of sTNFR-Fc expression by western blot assay.
Transduction of human microglial and neuroblastoma
cells
Briefly, 5 × 10
5 HTB-11 (neuronal) or CHME-5 (micro-
glial) cells were suspended in 0.4 mL RPMI 1640 med-
ium containing 8 μg/mL polybrene in a 1.5 mL tube,
and 0.1 mL of vector stock (5 × 10
7 IU/mL, MOI = 10)
was added and incubated at 37°C for 2 h. Infected cells
were then transferred into a 25 cm
2 tissue culture flask
with 2 mL of fresh growth medium and incubated at 37°
Cw i t h5 %C O 2. The medium was replaced 24 h post
infection (PI) and transduction efficiencies were evalu-
ated on day 3 PI. The percentage of GFP positive (GFP
+) cells was determined by calculating the number of
GFP+ and total cells from randomly selected micro-
scopic fields under a fluorescence microscope (Nikon
Eclipse TE2000-U). A total of 3 microscopic fields, con-
taining at least 100 cells each, were counted for each
transduction test.
Western blotting
The supernatant or lysate of transduced- or non-trans-
duced- cells including 293T, HTB-11, and CHME-5
cells, was mixed with an equal volume of 2X sodium
dodecyl sulfate (SDS) sample buffer (100 mM Tris-HCl
at pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.2% bromo-
phenol blue, and 20% glycerol) and loaded on 5% stack-
ing/12% separating SDS-polyacrylamide gels. Following
electrophoresis at 30 mA for 1 hr, separated proteins
were transferred onto a nitrocellulose membrane
(NCM) (Invitrogen, Carlsbad, CA). The membranes
were saturated with 1% bovine serum albumin (BSA)
(Sigma-Aldrich) in TBST buffer containing 10 mM Tris-
HCl at pH 8.0, 150 mM NaCl, and 0.05% Tween-20 for
1 h at room temperature (RT), followed by incubation
with diluted goat-anti-human IgG Fc (KPL, Maryland)
for 1 h at RT. Following extensive washing with TBST,
the NCM was incubated with diluted peroxidase-conju-
gated rabbit-anti-goat IgG (KPL, Maryland) at RT for 60
minutes, and then washed three more times with TBST
and exposed to a 3,3-diaminobenzidine tetrahydrochlor-
ide (DAB) substrate (PIERCE, Rockford, IL) for identifi-
cation of protein bands.
Enzyme-Linked Immunosorbent Assay (ELISA)
First, a 96-well plate was coated with a goat-anti-human
IgG-Fc antibody (KPL) overnight at 4°C. The plate was
then washed three times with 0.05% Tween-20 in PBS and
blocked with 1% BSA (Sigma-Aldrich) for 30 min at RT
on an orbital shaker. After washing three times with PBS,
the plate was incubated with diluted sTNFR-Fc containing
supernatant samples for 1 h and then incubated with a
biotin-conjugated goat-anti-human IgG Fc antibody
(Rockland, Gilbertsville, PA) for 1 h. The plate was then
washed and finally incubated with streptavidin-horseradish
peroxidase (Rockland) for 1 h at RT. The presence of
human sTNFR-Fc protein was detected with one-Step
Ultra TMB (tetramethylbenzidine) (Pierce). The enzymatic
reaction was stopped by addition of 1 M sulfuric acid. The
quantitation of sTNFR-Fc protein was based on the optical
density values at 450 nm, compared with a standard curve
of purified human sTNFR-Fc protein (R&D Systems,
Recombinant Human TNF RII/TNFRSF1B/Fc Chimera),
using an ELISA reader (Beckman Coulter AD340).
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay
MTT assay [26] was used for cytotoxicity tests. Briefly, test
cells at 20,000 cells/well were cultured in 96-well plates at
37°C with 5% CO2. After incubation for 24 h, each well
was treated with 10 μl MTT (5 mg/mL) for 4 h at 37°C.
Cell culture medium was then removed and 100 μlD M S O
was added to the wells. Plates were briefly shaken at 60
rpm for 5 min, to dissolve precipitate and remove bubbles,
and then read at 570 nm using a microplate reader
(Beckman Coulter AD340). The optical densities (OD) of
transduced and non-transduced cells at 570 nm were
compared and used for evaluating cellular viability.
Dot-immunobinding assay (DIBA)
Briefly, a nitrocellulose membrane (NCM) strip was
equilibrated in TBS and then air-dried. One microgram
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Tech Inc, New Jersey) was spotted onto a marked area
of the NCM and allowed to dry at RT for 30-45 min.
The loaded membranes were washed for 5 min in a
large volume of TBST and then saturated for 15 min
with 3% (w/v) BSA in TBS. The NCM was then incu-
bated for 1 h at RT with cell culture media collected
from either transduced or non-transduced control cells,
or with recombinant sTNFR-Fc protein (R&D Systems)
as a positive control. Following washing with TBST, the
membranes were incubated with goat-anti-human IgG
Fc-HRP conjugate (KPL) at RT for 1 h. After three
washes with TBST, the bound antibody was visualized
by incubation with diaminobenzidine (DAB) substrate
(Pierce) according to the manufacturer’s instruction.
Specific binding was visualized by the color deposition
on the NCM.
TNF-a blocking assay
L929 cells at exponential growth phase were harvested
and seeded in 96-well plates at a density of 2 × 10
4
cells/well and cultured at 37°C with 5% CO2.F o l l o w i n g
a 24-h incubation, cell culture medium was removed
and the cells were exposed to the following treatments:
0.1 mL of DMEM containing 8 ng of TNF-a alone;
0.1 mL of DMEM containing a mixture of 8 ng TNF-a
and 16 ng commercial recombinant sTNFR-Fc (R&D
Systems); or 0.1 mL of a 1:10 diluted conditioned med-
ium collected from either transduced or non-transduced
CHME-5 and HTB-11 cells, respectively, containing 8
ng of TNF-a. Triplicate wells were used for each of the
treatments including negative controls in which cells
were treated with 0.1 mL of DMEM containing no
TNF-a. These cultures were incubated at 37°C for 24 h
and the relative viability of test cells was then evaluated
by performing MTT assay. To examine whether secreted
sTNFR-Fc can block TNF-a mediated toxicity on neuro-
nal cells, HTB cells were treated similarly as described
for L929 cells. After 3 days of the treatment, cell viabi-
lity was determined through trypan blue exclusion assay.
Endogenous TNF-a assay
To rule out the possibility that lentiviral transduction of
the macrophage and/or neuronal cells might lead to cel-
lular activation and release of pro-inflammatory media-
tors such as TNF-a,T N F - a release from the vector-
transduced cells was measured by ELISA assay. Briefly,
1.0 × 10
4 cells (HTB-11 or CHME-5 transduced with Fc
fragment or non-transduced) were seeded into 96-well
plates in triplicate wells in 200 μlD M E Mc o n t a i n i n g
2.0% FBS. On day 3 post seeding of the cells, 100 μlo f
c o n d i t i o n e dm e d i u mf r o me ach well was collected and
used to coat 96-well ELISA plates overnight at 4°C. The
coated plate was blocked with 1% BSA for 30 min at RT
on an orbital shaker. After washing three times with
TPBS, the plate was incubated at RT for one hour with
100 μl of 1:10 diluted sTNFR-Fc containing supernatant
collected from transduced HTB-11, and the captured
sTNFR-Fc was then detected and quantitated with a
biotin-conjugated goat-anti-human IgG Fc antibody as
described in ELISA assay. This sensitivity cutoff of this
method was determined to be 5 pg/mL of TNF-a.
Neuroprotection assay
To evaluate the ability of the secreted sTNFR-Fc to pro-
tect primary rat neuronal cells from TNF-a mediated
neurotoxicity, conditioned medium from transduced
cells was collected at 48 h of cell growth. Collected
medium was diluted 1:10 with MEM containing no FBS,
after which it was directly added to primary cultures of
neuronal cells that were pre-exposed to HIV-1 Tat pro-
tein (500 nM). Control cells received Tat alone. Follow-
ing a 24-h incubation at 37°C, neuronal apoptosis was
measured by TUNEL assays. In addition, the neuropro-
tective ability of sTNFR-Fc was further verified by treat-
ing normal HTB-11 cells (2 × 10
4 cells/well) with
indicated amounts of Tat or gp120, exposing them to
conditioned medium from sTNFR-Fc producing cells,
and then measuring cell viability by trypan blue exclu-
sion assays.
Statistical analysis
Both one-way analysis of variance (ANOVA) followed by
aB o n f e r r o n i ’s multiple comparison test and t-test were
employed in this study for statistical analysis (using
Prism software). * indicates 0.01 < P ≤ 0.05; ** indicates
0.001 < P ≤ 0.01; *** indicates P ≤ 0.001.
Results
Characterization of gene transfer efficiency of the sTNFR-
Fc expressing lentiviral vector in human neuronal and
microglial cells
Human brain macrophage (CHME-5) and neuroblas-
toma (HTB-11) cell lines were transduced with lentiviral
vectors expressing sTNFR-Fc (Figure 1) at a MOI of 10,
and the efficiency of vector-mediated gene transfer was
evaluated at day 3 post transduction by counting the
number of GFP-positive cells using a fluorescence
microscope. The transduction efficiencies were deter-
mined to be 65 ± 5% and 100% for CHME-5 and HTB-
11 cells, respectively, following a single transduction
event (shown as ‘CHME-5-T1’ and ‘HTB-11T’;F i g u r e
2). Gene transfer efficiency in CHME-5 cells was
increased to 98 ± 2% following a second transduction
w i t ht h es a m ev e c t o r( C H M E - 5 - T 2 ;F i g u r e2 ) .I nt h e
vector constructs that were used, an enhanced green
fluorescent protein (eGFP) was co-expressed through an
IRES element to facilitate the monitoring of gene
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convenient assessment of the transfection and transduc-
tion efficiencies, it also led to an underestimation of vec-
tor-mediated gene expression, since genes expressed
through the IRES element are often expressed more
weakly than the promoter-proximal gene [27]. To
address this concern, sTNFR-Fc expression in CHME-5-
T1 cells was further analyzed by conducting indirect
immunofluorescence assays using goat anti-human IgG-
Fc antibody. Our results revealed that over 80% of the
CHME5 cells were sTNFR-Fc positive following a single
exposure to the vector (data not shown); this exceeded
the estimated gene transfer efficiency, as determined by
counting the number of GFP positive cells (65%).
Stable expression of sTNFR-Fc
Expression and secretion of sTNFR-Fc from the vector
construct was first examined by transfection in 293T
cells. Robust expression of GFP in transfected cells was
readily observed at transfection day 1 (data not shown).
To assess sTNFR-Fc protein production extracellularly
and intracellularly, culture supernatants and cell lysates
from both transfected cells and mock transfected cells
were collected/extracted and subjected to western blot
analysis. As shown in Figure 3A, there was no detection
of sTNFR-Fc expression in the supernatant from mock
transfected cells, while vector-transduced cells contain-
ing abundant expression of the sTNFR-Fc gene, both
within cells (cell lysate) and in secreted form (culture
supernatant). The mature, secreted form of sTNFR-Fc
migrated more slowly on SDS-PAGE than its intracellu-
lar form, with an approximate molecular weight of 95
kD for the secreted form of sTNFR-Fc and 80 kD for
the intracellular form of the protein. To confirm the
expression of sTNFR-Fc protein from the transduced
human neuronal cells, cell-free culture supernatants
were collected and subjected to immunoblot analysis. As
demonstrated in Figure 3B, sTNFR-Fc protein was read-
ily detected in the supernatant from vector-transduced
HTB-11 and CHME-5 cells; the molecular weight of the
secreted form of sTNFR-Fc was verified to be approxi-
mately 95 kD. When lysates from vector-transduced
cells were subjected to the same analysis, an immunor-
eactive protein of approximately 80 kD was detected.
We attribute the apparent difference in the size of the
mature, secreted form of the sTNFR-Fc protein relative
to its the intracellular form to post-translational modifi-
cation of the protein during the secretion process (e.g.,
glycosylation) [28].
To m the level of sTNFR-Fc in culture supernatants,
transduced cells were seeded at a density of 1.0 × 10
6
cells/mL in a 25 cm
2 flask and cultured at 37°C for 24
h. The supernatant was then collected and sTNFR-Fc
protein was quantified by ELISA. Results indicated that
concentration of the sTNFR-Fc in the supernatant of
CHME-5-T1 cells was 80 ± 2 ng/mL; after the second
transduction of the cells, the concentration increased to
117 ± 3 ng/mL (Figure 3C). The sTNFR-Fc level in the
supernatant from transduced HTB-11 cells was roughly
5-fold higher, at 520 ± 5 ng/mL, following a single
transduction. Importantly, sTNFR-Fc expression was not
detected in media collected from non-transduced nor-
mal CHME-5 and HTB-11 cells under the same condi-
tions (data not shown).
Figure 2 Photomicrographs of lentiviral vector transudced CHME and HTB cells showing GFP expression. CHME and HTB cells at
exponential growth phase were transduced by the lentiviral vector at an MOI of 10 and transduction efficiency was evaluated by counting the
percentage of GFP-positive cells within a transduced cell population using a fluorescence microscope (Nikon Eclipse TE2000-U).
Photomicrographs showing transduced cells under phase contrast (PC) bright light or fluorescent light (FL) at 488 nm were taken at
magnifications of 100× originally and scale bars in the pictures denote 100 μm. CHME-NT = non-transduced normal CHME cells; CHME-T1 = one
transduction and CHME-T2 = two transductions; HTB-NT = non-transduced HTB cells and HTB-T = transduced HTB cells.
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and secretion, the transduced CHME-5 and HTB-11
cells were serially subcultured 20 times, and sTNFR-Fc
levels in the conditioned supernatants were measured by
ELISA at every 5
th passage, with supernatants collected
from corresponding non-transduced cells being used as
negative controls. No significant reduction in the
sTNFR-Fc expression levels was detected over the
course of the 20 passages (Figure 3C). The percentage
of GFP positive cells in these transduced cell popula-
tions was also evaluated every five passages, and found
to be stable over the course of the 20 passages (Figure
3D). These results suggest that the lentiviral vector
mediated transduction and sTNFR-Fc secretion was
stable and remained at high levels over a prolonged
time period.
Potential adverse impact
To determine whether transduction with the lentiviral-
TNFR-Fc vector resulted in any adverse impact on tar-
get cells, the transduced cells were examined for their
growth kinetics and morphology. There were no obvious
alterations in cell morphology following transduction,
which remained unchanged at different passage numbers
(not shown). Subsequent MTT assays also indicated that
there was no statistically significant difference in cellular
viability (mitochondrial energy metabolism) between
transduced and non-transduced control cells (Figure 4).
Figure 3 Stable and high level secretion of sTNFR-Fc in transduced cells. (A) Immunoblot detection of sTNFR-Fc protein in transfected cells.
Mock = supernatant from mock transfected 293T cells; Intracellular = transfected cell lysate; and Secreted = supernatant from the transfected
293T cells. (B) Immunoblot detection of sTNFR-Fc protein in transduced cells intracellularly (cell lysate) and extracellularly (supernatant). HTB-T =
transduced HTB-11 cells; CHME-T2 = CHME-5 cells transduced twice with the vector; CHME-T1 = CHME-5 cells transduced once with the vector.
(C) Stable expression of sTNFR-Fc protein in conditioned medium of transduced cells. Expression of sTNFR-Fc in supernatants from transduced
cells was measured by ELISA; results shown at different cell passages represent mean values from three independent experiments and error bars
denote the standard deviation. (D) Stable expression of GFP in lentivirus vector-transduced cells. Transduced cells were passed in vitro and the
percentage of GFP positive cells was determined every 5 passages by calculating the percentage of GFP+ cells within the culture using an
inverted fluorescent microscope (Nikon Eclipse TE2000-U) with a digital camera attachment. Data presented here represent mean values from at
least three independent experiments and error bars denote the standard deviation.
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tion of CHME-5 or HTB-11 cells resulted in their
inflammatory activation. To do this, we measured and
compared endogenous TNF-a release by cells trans-
duced with a control lentiviral vector encoding the Fc
fragment alone, or non-transduced cells. As shown in
Figure 5, endogenous TNF-a release by the vector-
transduced macrophage (CHME-5) or neuronal (HTB-
11) cells was not significantly higher than that produced
by non-transduced cells, indicating that lentiviral trans-
duction did not stimulate the target cells for increased
secretion of pro-inflammatory cytokines such as TNF-a.
Biological function of constitutively expressed sTNFR-Fc
The biological function of the secreted sTNFR-Fc pro-
tein was evaluated and confirmed by three different
methods. First, a dot immunoblot assay (DIBA) was
performed to determine whether the expressed sTNFR-
Fc was able to recognize TNF-a.A ss h o w ni nF i g u r e6 ,
sTNFR-Fc secreted from both HTB-11 and CHME-5
cells had the ability to bind to TNF-a in vitro. Second,
the ability of the sTNFR-Fc to antagonize the toxic
activity of TNF-a was assessed by using TNF-a-sensi-
tive L929 indicator cells. In this case, an MTT assay
was conducted to determine if the secreted sTNFR-Fc
protein was able to protect the test L929 cells from the
cytotoxic impact of exogenous TNF-a.I nt h i se x p e r i -
ment, L929 cells that were exposed to TNF-a in the
presence of the culture supernatant (1:10 dilution)
from non-transduced control HTB and CHME-5 cells
exhibited greatly reduced viability (54+0.7% and 52
+0.7%, respectively). In contrast, L929 cells that were
exposed to TNF-a i nt h ep r e s e n c eo fc o n d i t i o n e d
media (also diluted 1:10) from vector-transduced
HTB and CHME cells were protected from cell killing
(viability was 75 + 1.2 and 66 ± 1.4%, respectively)
(Figure 7). Control studies confirmed that cells exposed
to TNF-a alone underwent high levels of cell death
(53 ± 0.9% cell viability), while cells exposed to TNF-a
in the presence of 160 ng/mL of commercially avail-
able, recombinant sTNFR-Fc (rTNFR) were strongly
protected (85 ± 1.4% cell viability). These data indicate
Figure 4 Comparative analysis of the viability of transduced
cells following vector transduction with parental control cells
by MTT assay. The OD570 value for non-transduced cells was
arbitrarily defined as 100% cell viability, and data from vector
transduced cells was then normalized relative to this. No significant
difference was detected among non-transduced (NT), vector-
transduced (T), and empty-vector transduced (Fc) CHME (A) and
HTB (B) cells (p > 0.05). Results shown represent mean values from
three independent experiments and error bars denote the standard
deviation.
Figure 5 Transduction with lentivirus vectors does not result in
inflammatory activation of CHME-5 or HTB-11 cells. Endogenous
TNF-a secretion into the conditioned media of cells was measured
by ELISA. Cells tested were as follows: CHME-NT, HTB-NT: non-
transduced CHME-5 or HTB-11 cells; CHME-Fc, HTB-Fc: CHME-5 or
HTB-11 cells transduced with the empty vector expressing Fc
fragment. Results shown represent mean levels of TNF-a expression
from three independent experiments and error bars denote the
standard deviation.
Figure 6 Specific binding of expressed sTNFR-Fc to TNF-a by
dot immunoblot assay. One microgram of standard recombinant
human TNF-a protein was spotted onto nitrocellular membrane
(NCM) and then blocked and incubated with supernatants from
normal and transduced cells. After three washes with TBST, a goat-
anti-human IgG Fc-HRP conjugate was applied and incubated at RT
for 1 h. Specific binding was visualized by color deposition on the
NCM following incubation with diaminobenzidine (DAB) substrate.
Lanes: HTB-NT = supernatant from non-transduced HTB-11 cells and
CHME-NT = supernatant from non-transduced CHME-5 cells used as
negative controls; HTB-T = supernatant collected from transduced
HTB-11 cells and CHME-T2 = supernatant from transduced CHME-5
cells; and C
+ = purified recombinant sTNFR-Fc protein as a positive
control.
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Page 7 of 11that the sTNFR-Fc secreted from vector-transduced
cells mediated a significant cytoprotective effect, reflec-
tive of its ability to neutralize the biological activity
of TNF-a. The purified rTNFR mediated a slightly
higher level of cytoprotection (85 ± 1.4% cell viability)
compared to 1:10 diluted conditioned medium from
vector-transduced HTB and CHME cells (75 + 1.2
and 66 ± 1.4% cell viability, respectively). This reflects
the higher concentration of purified rTNFR in this
experiment (160 ng/mL), when compared to the
level of sTNFR-Fc present in 1:10 diluted cell culture
supernatants from the vector-transduced cells (see
Figure 3C).
As expected, conditioned medium from the control
lentiviral-Fc vector transduced cultures had no protec-
tive effect on the L929 cells exposed to TNF-a (data not
shown). Similarly, sTNFR-Fc expressed from the trans-
duced macrophages (CHME-5) and neuronal cells
(HTB-11) was able to protect normal HTB-11 cells from
TNF-a mediated toxicity (Figure 8A) and transduced
HTB-11 cells expressing sTNFR-Fc were also protected
from TNF-a mediated toxicity (Figure 8B).
To evaluate the ability of the secreted sTNFR-Fc pro-
tein to block HIV-1 Tat-mediated neurotoxicity, primary
rat neurons were treated with recombinant HIV-1 Tat
protein in the presence or absence of conditioned
medium from vector-transduced cells, and cellular apop-
tosis was then measured 24 hours later by TUNEL
assay. For this experiment, only culture supernatants
from transduced HTB-11 cells were tested, since they
contain roughly 5-fold higher levels of sTNFR-Fc
expression as compared to supernatants from trans-
duced CHME-5 cells (Figure 3C). Neurons exposed to
either Tat alone or Tat plus conditioned medium from
non-transduced control HTB-11 cells exhibited high
levels of apoptosis, as reflected by TUNEL-positive cells
(30.7%) while cells exposed to Tat plus conditioned
medium from sTNFR-Fc vector-transduced HTB-11
cells exhibited a greatly reduced level of apoptosis
(14.2%) (Figure 8C). Since HIV-1 Tat induces neuronal
death via production of TNF-a [29-31], our results
show that the secreted sTNFR-Fc protein was able to
significantly reduce HIV-1 Tat-mediated neurotoxicity
by neutralizing TNF-a.
Next, the possibility of blocking the neurotoxicity
mediated by HIV-1 gp120, or the synergistic neurotoxi-
city by gp120 and Tat, was evaluated. As shown in
Figure 8D, when HTB-11 cells were treated with 100
ng/mL gp120 for three days, cell viability in cultures co-
treated with conditioned media from the sTNFR-Fc vec-
tor transduced cells was significantly higher than that in
cultures co-treated with conditioned media from the Fc
vector transduced cells, or in cultures co-treated with
conditioned media from the non- transduced cells
(71.9% ± 3.59% VS 49.9% ± 4.76% and 55.2% ± 2.26%
respectively). The secreted sTNFR-Fc protein also pro-
tected HTB-11 target cells from the combined treatment
of HIV-1 gp120 and Tat. In cultures treated with 100
ng/mL gp120 plus 250 ng/mL Tat, cell viability was dra-
matically increased in cultures that were co-treated with
conditioned media from sTNFR-Fc vector transduced
cells (47.9% ± 3.17%), compared to cultures co-treated
with conditioned media from the Fc vector transduced
or non- transduced cells (13.0% ± 1.66% and 13.2% ±
1.78%, respectively). These results were confirmed when
a higher concentration of gp120 was used (250 ng/mL)
in similar experiments (Figure 8D).
Discussion
This study employed a lentiviral vector to deliver and
express a soluble TNF receptor decoy in microglial and
neuronal cells, as a means of protecting cells from TNF-
mediated cytotoxicity. The results indicated that both
microglial and neuronal cells could be efficiently trans-
duced with the sTNFR-Fc expressing vectors, and the
transduced cells showed long-term and stable expression
and secretion of sTNFR-Fc. With respect to the expres-
sion levels of sTNFR-Fc in these two cell types, quanti-
tative analysis of vector-mediated gene transfer revealed
that transduction of the neuroblastoma cells was
Figure 7 Functional antagonization of sTNFR-Fc against TNF-a.
As described in materials and methods, TNF-a sensitive L929 cells
were treated with TNF-a alone (80 ng/mL) or with TNF-a plus
culture supernatants from vector-transduced cells; purified
recombinant sTNFR-Fc protein (160 ng/mL) was used as a positive
control. After incubation for 24 h, cell viability was then evaluated
by MTT assay. Viability was significantly higher for the cells treated
with conditioned medium from transduced cells expressing hTNFR-
Fc (** p < 0.01 for HTB-T; *p < 0.05 for CHME-T) when compared to
cultures that received TNF-a alone, or TNF-a plus culture
supernatants from parental cells (CHME-N and HTB-N). Results
shown represent mean levels of three independent experiments
and error bars denote the standard deviation.
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Page 8 of 11considerably more efficient than that of the microglial
cells. Although the transduction efficiency of the micro-
glial cells was increased to 100% after a second round of
transduction, the level of sTNFR-Fc secretion from the
transduced cells was still much less than that of the
transduced neuronal cells. A potential explanation for
this difference in protein expression levels is that HTB-
11 cells may have a higher integrated vector copy num-
ber of the vector than CHME-5 cells. This is consistent
with previous observations that neural cells are more
Figure 8 sTNFR-Fc mediated protection of neuronal cells from TNF-a, HIV-Tat and gp120. (A) Non-transduced human neuronal cells, HTB-
11, were treated with TNF-a alone (80 ng/mL), or with TNF-a plus culture supernatants (1:10 dilution) from vector-transduced cells (as indicated).
Cells were incubated at 37°C for 3 days, and viability of the cells was determined by the trypan blue exclusion assay. sTNFR-Fc = supernatant
collected from HTB-11 or CHME-5 cells transduced with the hTNFR-Fc encoding vector; Fc = supernatant collected from HTB-11 or CHME-5 cells
transduced with the vector encoding human Fc only; rTNFR = purified commercial recombinant TNFR-Fc protein (160 ng/mL), used as a positive
control. Results shown represent mean levels of three independent experiments and error bars denote the standard deviation. (B) Vector
transduced human HTB-11 cells were exposed to TNF-a as described in 7A. HTB-11 cells transduced either with the sTNFR-Fc or Fc encoding
vector were used in this experiment, along with non-transduced cells as controls. Results shown represent mean levels of three independent
experiments and error bars denote the standard deviation. (C) sTNFR-Fc protects primary rat neurons against HIV-1 Tat-mediated toxicity.
Medium from vector-transduced or parental HTB-11 cells was collected at day 10, diluted and mixed with 500 nM HIV-1 Tat protein, prior to
addition to primary rat neurons. Following 24 hours incubation at 37°C, these test cultures along with the control were analyzed by TUNEL
assay. Cell death was significantly reduced in neuronal cultures that were treated with Tat plus conditioned medium from HTB-11 cells
transduced with the sTNRF-Fc encoding lentiviral vector (HTB-T 10d) versus cells treated with Tat plus conditioned medium from parental HTB-
11 cells (HTB 10d) (*p < 0.01). NT, normal neuronal cells received no Tat, and -, neuronal cells exposed to Tat as a positive control. Results shown
represent mean levels of three independent experiments and error bars denote the standard deviation. (D) sTNFR-Fc mediated neuronal
protection of human HTB-11 cells against HIV-1 gp120 toxicity. Conditioned media from hTNFR-Fc or Fc vector transduced HTB-11 cells were
collected, diluted and mixed with 100 ng/mL (gp120A) or 250 ng/mL (gp120B) HIV-1 gp120 protein, with or without HIV-1 Tat, prior to addition
to HTB-11 cells. Following 3 days incubation at 37°C, cell viability of these cultures, together with control cultures, was determined by trypan
blue exclusion assay (***p < 0.001). Results shown represent mean levels of three independent experiments and error bars denote the standard
deviation.
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Page 9 of 11readily transduced by HIV-1 based vectors than cells of
myeloid lineage such as macrophages [32]. Alternatively,
it is possible that there may be an intrinsic difference in
the ability of the two cell types to produce and secrete
sTNFR-Fc.
Regardless of the overall efficiency of vector-mediated
gene transfer, lentiviral mediated transduction of
sTNFR-Fc into neural and microglial cells did not result
in any measurable decrease in cell viability. Moreover,
transgene expression (of both TNFR-Fc and GFP) was
stable in transduced cells over 20 in vitro passages. Not
only was the expression level stable over time, but also
the secreted sTNFR-Fc decoy was shown to be consis-
tently biologically active. DIBA analysis demonstrated
that the secreted sTNFR-Fc decoy bound directly to
TNF-a, and cell based functional assays revealed that
sTNFR-Fc was able to efficiently block TNF-a mediated
cytotoxic effects in L929 and HTB-11 cells. Finally, the
secreted sTNFR-Fc protein produced by vector-trans-
duced cells was able to protect primary rat neurons and
cultured human neuronal cells from HIV-1 Tat and
gp120 mediated neurotoxicity, as well as the synergistic
neurotoxicity mediated by gp120 and Tat. These find-
ings are significant since HIV-1 Tat is a major virus-
derived neurotoxin releasedb yi n f e c t e dm a c r o p h a g e s
and microglia [30,31,33,34], and gp120 exerts synergistic
neurotoxicity with Tat [35,36]. The fact that TNF-a is a
major contributor to HIV-1 Tat and gp120 mediated
neurotoxicity [37-41] likely explains why sTNFR-Fc is
neuroprotective in this setting.
Conclusions
We constructed an HIV-1-based vector that efficiently
transduced human neural and microglial cells, resulting
in stable expression and secretion of high levels of
sTNFR-Fc. The secreted sTNFR-Fc protein antagonized
the biological activity of TNF-a. The secreted sTNFR-Fc
protein antagonized the biological activity of TNF-a and
protected neuronal cells from HIV-1 Tat-mediated neu-
rotoxicity. These data show that lentiviral vector
mediated sTNFR-Fc expression may represent an effec-
tive neuroprotective strategy in the context of neu-
roAIDS. Future efforts to develop this approach further
will focus on the establishment of effective methods for
ex vivo transduction of monocytes using the constructed
lentiviral vector, and use of gene-modified monocytes to
deliver the therapeutic transgene into the CNS, follow-
ing migration across the BBB. We believe that this
approach has significant potential given the overall
favorable safety profile associated with non-CNS pene-
trant TNF-a inhibitors (including sTNFR-Fc) for treat-
ment of rheumatoid arthritis and other conditions.
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